• Science
  • Pipeline
  • News
  • About
  • Careers
  • Contact
Ultra-Rapid, Low-Cost Neutralizing Antibody Therapeutic for COVID-19

Ultra-Rapid, Low-Cost Neutralizing Antibody Therapeutic for COVID-19

by admin | Mar 18, 2021 | Press Release

Beyond the lung: treating the GI symptoms of Covid-19

Beyond the lung: treating the GI symptoms of Covid-19

by admin | Feb 16, 2021 | Press Release

High Impact Drugs at Dirt Cheap Cost

High Impact Drugs at Dirt Cheap Cost

by admin | Feb 12, 2021 | News

Delhi belly. Montezuma’s Revenge. The Aztec two-step. Here in the West, we like to slap whimsical names on traveler’s diarrhea. For those of us blessed with ready access to food and sanitary infrastructure, these diseases are a minor inconvenience. Those in the...
CARB-X awards $5.3M to Lumen for diarrheal disease research, development

CARB-X awards $5.3M to Lumen for diarrheal disease research, development

by admin | Feb 12, 2021 | Press Release

Lumen Bioscience Receives CARB-X Award to Develop Preventative for Deadly Diarrheal Diseases and Details Broad Potential of Spirulina Platform

Lumen Bioscience Receives CARB-X Award to Develop Preventative for Deadly Diarrheal Diseases and Details Broad Potential of Spirulina Platform

by admin | Feb 12, 2021 | Press Release

« Older Entries
Next Entries »

Recent Post

  • Cognition Live Article on RePreve Trial
  • LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
  • Preventive antimicrobials: A promising solution to antibiotic resistance
  • Image Credit: © bukhta79 | stock.adobe.comPreventive Biologics May Aid the Antibiotic Resistance Crisis
  • Q&A: Biologic drugs are reinvented to treat infectious diseases

Follow on

  • Follow
  • Follow
  • Follow

  • Science
  • Pipeline
  • News
  • About

  • Careers
  • Contact
  • Privacy Policy
  • PO Terms

  • Expanded Access Policy
  • FCOI
  • Services
  • iLumenate Newsletter

©2024 Lumen Bioscience, Inc.